Comparative effectiveness of screening strategies for colorectal cancer

Cancer

Volumn 123, Issue 9, 2017, Pages 1516-1527

  Barzi, Afsaneh ^a   Lenz, Heinz Josef ^a   Quinn, David I ^a   Sadeghi, Sarmad ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

cancer prevention; colonoscopy; colorectal cancer; DNA testing; screening

Indexed keywords

ADULT; AGED; ARTICLE; CANCER RISK; CANCER SCREENING; CAUSE OF DEATH; COLONOSCOPY; COLORECTAL CANCER; COMPUTED TOMOGRAPHIC COLONOGRAPHY; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; FECES ANALYSIS; FOLLOW UP; HUMAN; IMMUNOCHEMISTRY; OCCULT BLOOD TEST; POPULATION RESEARCH; SENSITIVITY AND SPECIFICITY; SIGMOIDOSCOPY; STOOL DNA TESTING; UNITED STATES; ADENOCARCINOMA; ADENOMA; CHEMISTRY; COLORECTAL NEOPLASMS; COMPARATIVE STUDY; COMPUTER SIMULATION; COST BENEFIT ANALYSIS; EARLY CANCER DIAGNOSIS; ECONOMICS; FECES; FEMALE; HEALTH CARE COST; MALE; MARKOV CHAIN; MIDDLE AGED; OCCULT BLOOD; PROCEDURES;

DNA; HEMOGLOBIN;

ADENOCARCINOMA; ADENOMA; AGED; COLONOGRAPHY, COMPUTED TOMOGRAPHIC; COLONOSCOPY; COLORECTAL NEOPLASMS; COMPUTER SIMULATION; COST-BENEFIT ANALYSIS; DNA, NEOPLASM; EARLY DETECTION OF CANCER; FECES; FEMALE; HEALTH CARE COSTS; HEMOGLOBINS; HUMANS; MALE; MARKOV CHAINS; MIDDLE AGED; OCCULT BLOOD; SIGMOIDOSCOPY;

EID: 85018759975     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.30518     Document Type: Article

References (42)

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66:7–30.
2. DeSantis C, Naishadham D, Jemal A. Cancer statistics for African Americans, 2013. CA Cancer J Clin. 2013;63:151–166.
3. Vogelaar I, van Ballegooijen M, Schrag D, et al. How much can current interventions reduce colorectal cancer mortality in the US? Mortality projections for scenarios of risk-factor modification, screening, and treatment. Cancer. 2006;107:1624–1633.
4. Zauber AG, Winawer SJ, O'Brien MJ, et al. Colonoscopic polypectomy and long-term prevention of colorectal-cancer deaths. N Engl J Med. 2012;366:687–696.
5. Cress RD, Morris C, Ellison GL, et al. Secular changes in colorectal cancer incidence by subsite, stage at diagnosis, and race/ethnicity, 1992-2001. Cancer. 2006;107:1142–1152.
6. Nishihara R, Wu K, Lochhead P, et al. Long-term colorectal-cancer incidence and mortality after lower endoscopy. N Engl J Med. 2013;369:1095–1105.
7. Siegel RL, Ward EM, Jemal A. Trends in colorectal cancer incidence rates in the United States by tumor location and stage, 1992-2008. Cancer Epidemiol Biomarkers Prev. 2012;21:411–416.
8. Chang GJ, Hu CY, Eng C, et al. Practical application of a calculator for conditional survival in colon cancer. J Clin Oncol. 2009;27:5938–5943.
9. Doubeni CA, Weinmann S, Adams K, et al. Screening colonoscopy and risk for incident late-stage colorectal cancer diagnosis in average-risk adults: a nested case-control study. Ann Intern Med. 2013;158:312–320.
10. Weinstein MC, O'Brien B, Hornberger J, et al. Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices—Modeling Studies. Value Health. 2003;6:9–17.
11. Husereau D, Drummond M, Petrou S, et al. Consolidated Health Economic Evaluation Reporting Standards (CHEERS)—explanation and elaboration: a report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force. Value Health. 2013;16:231–250.
12. Gold MR, Siegel JE, Russell LB, Weinstein MC, eds. Cost-Effectiveness in Health and Medicine. New York: Oxford University Press; 1996.
13. Walker DG, Wilson RF, Sharma R, et al. Best Practices for Conducting Economic Evaluations in Health Care: A Systematic Review of Quality Assessment Tools. Report 12-EHC 132-EF. Rockville, MD: Agency for Healthcare Research and Quality; 2012.
14. Allison JE, Sakoda LC, Levin TR, et al. Screening for colorectal neoplasms with new fecal occult blood tests: update on performance characteristics. J Natl Cancer Inst. 2007;99:1462–1470.
15. Knudsen AB, Zauber AG, Rutter CM, et al. Estimation of benefits, burden, and harms of colorectal cancer screening strategies: modeling study for the US Preventive Services Task Force. JAMA. 2016;315:2595–2609.
16. Zauber AG, Lansdorp-Vogelaar I, Knudsen AB, Wilschut J, van Ballegooijen M, Kuntz KM. Evaluating test strategies for colorectal cancer screening: a decision analysis for the US Preventive Services Task Force. Ann Intern Med. 2008;149:659–669.
17. van Rijn JC, Reitsma JB, Stoker J, Bossuyt PM, van Deventer SJ, Dekker E. Polyp miss rate determined by tandem colonoscopy: a systematic review. Am J Gastroenterol. 2006;101:343–350.
18. Whitlock EP, Lin J, Liles E, et al. Screening for Colorectal Cancer: An Updated Systematic Review. Rockville, MD: Agency for Healthcare Research and Quality; 2008.
19. Imperiale TF, Ransohoff DF, Itzkowitz SH. Multitarget stool DNA testing for colorectal-cancer screening. N Engl J Med. 2014;371:187–188.
20. Imperiale TF, Ransohoff DF, Itzkowitz SH, et al. Multitarget stool DNA testing for colorectal-cancer screening. N Engl J Med. 2014;370:1287–1297.
21. Zauber AG, Knudsen AB, Rutter CM, et al. Cost-Effectiveness of CT Colonography to Screen for Colorectal Cancer. Rockville, MD: Agency for Healthcare Research and Quality; 2009.
22. Halligan S, Altman DG, Taylor SA, et al. CT colonography in the detection of colorectal polyps and cancer: systematic review, meta-analysis, and proposed minimum data set for study level reporting. Radiology. 2005;237:893–904.
23. Imperiale TF, Wagner DR, Lin CY, et al. Using risk for advanced proximal colonic neoplasia to tailor endoscopic screening for colorectal cancer. Ann Intern Med. 2003;139:959–965.
24. Mandel JS, Bond JH, Church TR, et al. Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study. N Engl J Med. 1993;328:1365–1371.
25. Holme O, Loberg M, Kalager M, et al. Effect of flexible sigmoidoscopy screening on colorectal cancer incidence and mortality: a randomized clinical trial. JAMA. 2014;312:606–615.
26. Joseph DA, King JB, Miller JW, et al. Prevalence of colorectal cancer screening among adults—Behavioral Risk Factor Surveillance System, United States, 2010. MMWR Morb Mortal Wkly Rep. 2012;61(suppl):51–56.
27. Hardcastle JD, Chamberlain JO, Robinson MH, et al. Randomised controlled trial of faecal-occult-blood screening for colorectal cancer. Lancet. 1996;348:1472–1477.
28. Zauber AG, Lansdorp-Vogelaar I, Knudsen AB, Wilschut J, van Ballegooijen M, Kuntz KM. Evaluating Test Strategies for Colorectal Cancer Screening—Age to Begin, Age to Stop, and Timing of Screening Intervals: A Decision Analysis of Colorectal Cancer Screening for the US Preventive Services Task Force from the Cancer Intervention and Surveillance Modeling Network (CISNET). Report No. 08–05124-EF-2 (US Preventive Services Task Force, formerly Systematic Evidence Reviews). Rockville, MD: Agency for Healthcare Research and Quality; 2009.
29. Zauber AG, Lansdorp-Vogelaar I, Wilschut J, Knudsen AB, van Ballegooijen M, Kuntz KM. Cost-Effectiveness of DNA Stool Testing to Screen for Colorectal Cancer. AHRQ Technology Assessments. Rockville, MD: Agency for Healthcare Research and Quality; 2007.
30. National Cancer Institute, Surveillance Research Program. Standard Populations (Millions) for Age-Adjustment. Volume 2015. Bethesda, MD: Surveillance Research Program, National Cancer Institute; 2012.
31. Surveillance, Epidemiology, and End Results (SEER) Program (http://www.seer.cancer.gov) SEER*Stat Database: Incidence-SEER 9 Regs Research Data, Nov 2014 Sub (1973–2012). Posted to the SEER website, April 2015 (http://www.seer.cancer.gov). Bethesda, MD: National Cancer Institute, Division of Cancer Control and Population Sciences, Surveillance Research Program, Surveillance Systems Branch; 2015.
32. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. Fort Washington, PA: NCCN; 2016. Available at: http://www.nccn.org.
33. Arias E. United States life tables, 2010. Statistics reports; Hyattsville, MD: National Center for Health Statistics. 2014;63:7. Available at: http://www.cdc.gov/nchs/data/nvsr/nvsr63/nvsr63_07.pdf.
34. Hirth RA, Chernew ME, Miller E, et al. Willingness to pay for a quality-adjusted life year: in search of a standard. Med Decis Making. 2000;20:332–342.
35. Neumann PJ. Using Cost-Effectiveness Analysis to Improve Health Care: Opportunities and Barriers. New York: Oxford University Press; 2005.
36. Schoen RE, Pinsky PF, Weissfeld JL, et al. Colorectal-cancer incidence and mortality with screening flexible sigmoidoscopy. N Engl J Med. 2012;366:2345–2357.
37. Knudsen AB, Lansdorp-Vogelaar I, Rutter CM, et al. Cost-effectiveness of computed tomographic colonography screening for colorectal cancer in the Medicare population. J Natl Cancer Inst. 2010;102:1238–1252.
38. Lansdorp-Vogelaar I, Kuntz KM, Knudsen AB, Wilschut JA, Zauber AG, van Ballegooijen M. Stool DNA testing to screen for colorectal cancer in the Medicare population: a cost-effectiveness analysis. Ann Intern Med. 2010;153:368–377.
39. US Preventive Services Task Force, Bibbins-Domingo K, Grossman DC, et al. Screening for colorectal cancer: US Preventive Services Task Force Recommendation Statement. JAMA. 2016;315:2564–2575.
40. Mulhall BP, Veerappan GR, Jackson JL. Meta-analysis: computed tomographic colonography. Ann Intern Med. 2005;142:635–650.
41. Barzi A, Sadeghi S, Kattan MW, Meropol NJ. Comparative effectiveness of screening strategies for Lynch syndrome. J Natl Cancer Inst. 2015;107:pii: djv005.
42. Song X, Zhao Z, Barber B, Gregory C, Cao Z, Gao S. Cost of illness in patients with metastatic colorectal cancer. J Med Econ. 2011;14:1–9.